
GSK teams up with Strathclyde and University of Nottingham
pharmafile | July 16, 2019 | News story | Manufacturing and Production | GSK, GlaxoSmithKline, UK, britain, pharma, universities
GlaxoSmithKline has teamed up with the University of Nottingham and the University of Strathclyde for a five-year partnership aimed at promoting new medical research.
The £12.9 million project has received £5.5 million in funding from the Engineering and Physical Sciences Research Council (ESPRC).
The partnership will see the three organisations team up to use machine learning and AI to identify new medicines and make the production of medicines more environmentally friendly.
The project is also intended to train a new cohort of postgraduate students and postdoctoral researchers.
Tony Wood, Senior Vice President, Medicinal Science & Technology at GSK said: “We are delighted with the EPSRC award which recognises the important work being done in collaboration with Nottingham and Strathclyde Universities.
“Together we are focused on the application of Artificial Intelligence/Machine Learning in synthetic chemistry, a discipline that is central to drug design and development of new medicines. The additional support will enable continued research hopefully delivering efficiency gains that bring meaningful benefit to the discovery of new medicines.”
Louis Goss
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …






